PILA PHARMA is a privately held clinical stage pharmaceutical company based in Malmö, Sweden.
PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes.
XEN-D0501, the recently purchased, safe clinical development candidate, will enter the first clinical trials in type-2 diabetic patients in 2017.


Investor presentation at ‘Next Big Thing’ (by Blasieholmen Investment Group)
Moderna Museet, Stockholm, Sweden

Watch the presentation here
Direct link to presentation here

Meet us at

San Diego, CA
June 9-13, 2017
the American Diabetes Association’s
77th Scientific Sessions


San Diego, CA
June 19-22, 2017
The BIO International Convention

DorteX Gram

“Min uppfinning kom och hämtade tillbaka mig”
Dr. Dorte X. Gram, CEO of PILA Pharma was interviewed by Sydsvenskan, Sweden.

Read the article in swedish here


We are proud to be on the cover of the September 2016 issue of Nordic Life Science Magazine as representatives of Nordic Life Science companies.

Read the article here
Read the magazine here


At BioEurope Spring in Stockholm in April 2016 Dr. Dorte X. Gram, CEO of PILA Pharma was interviewed by the organizers about the current status and our plans going forward.

Please find the links below: